Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood.2025029108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Clinical features of acute B lymphoblastic leukemia with TAF15::ZNF384 fusion gene].
Zhonghua Yi Xue Za Zhi
September 2025
Department of Laboratory Medicine, Hebei Yanda Ludaopei Hospital, Langfang 065201, China Beijing Ludaopei Institute of Hematology, Department of Pathology &Laboratory Medicine, Beijing Ludaopei Hospital, Beijing 100176, China.
A retrospective analysis was conducted on the clinical data of acute B lymphoblastic leukemia (B-ALL) patients with TAF15::ZNF384 fusion gene positive at Hebei Yanda Ludaopei Hospital from December 2018 to February 2022. The patients were followed up until December 2024 to analyze their clinical characteristics and outcomes. A total of 6 patients were included, including 4 males and 2 females, aged 16 to 47 years.
View Article and Find Full Text PDFRare Atypical Ela3 BCR-ABL transcript in acute Lymphoblastic Leukemia: a case report.
Afr Health Sci
June 2025
Department of Hematology, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, China.
The Philadelphia chromosome is usually express on about 30% acute B lymphoblastic leukemia. Most of Ph-positive acute lymphoblastic leukemia patients have ela2 BCR-ABL transcripts, other atypical fusion genes such as ela3 have been rare reported. We reported a case of Ph-positive B-acute lymphoblastic leukemia with a scare ela3 fusion transcript.
View Article and Find Full Text PDFB-Lymphoblastic Leukemia With TCF3::PBX1 Fusion Presenting a Mature B-Cell Phenotype and Lambda Light-Chain Restriction.
Pediatr Blood Cancer
August 2025
Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China.
The expression of CD109 in B-cell acute lymphoblastic leukemia and its potential as a promising marker for minimal residual disease (MRD) detection.
Clin Exp Med
August 2025
Laboratory of Hematology, Second Hospital of Shanxi Medical University, The Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province, 382 Wuyi Road, Taiyuan, 030001, China.
Background: CD109 is overexpressed in various tumors, but its role in hematologic malignancies, particularly acute B lymphoblastic leukemia (B-ALL), remains unclear.
Methods: CD109 expression was assessed at both mRNA and protein levels in B-ALL patients using real-time quantitative PCR (RQ-PCR) and multiparameter flow cytometry (MFC). The relationship between CD109 expression and clinical and laboratory parameters was examined.
and Other Candidate Genes as Potential Biomarkers of Therapy Resistance in B-ALL: Insights from Chromosomal Microarray Analysis and Machine Learning.
Int J Mol Sci
August 2025
National Medical Research Center for Hematology, 125167 Moscow, Russia.
Chromosomal microarray analysis (CMA) was performed for 40 patients with B-ALL undergoing treatment according to the ALL-2016 protocol to investigate the copy number alterations (CNAs) and copy neutral loss of heterozygosity (cnLOH) associated with minimal residual disease (MRD)-positive remission. Aberrations involving over 20,000 genes were identified, and a random forest approach was applied to isolate a subset of genes whose CNAs and cnLOH are significantly associated with poor therapeutic response. We have assembled the triple matched healthy population data and used that data as a reference, but not as a matched control.
View Article and Find Full Text PDF